Inverse association of the endogenous thrombin potential (ETP) with cardiovascular death: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study

International Journal of Cardiology

Volumn 176, Issue 1, 2014, Pages 139-144

  Schneider, Jochen G ^a,b   Isermann, Berend ^c   Kleber, Marcus E ^d,e   Wang, Hongjie ^c   Boehm, Bernhard O ^f,g   Grammer, Tanja B ^d   Prueller, Florian ^h   Nawroth, Peter P ^d   Maerz, Winfried ^d,h,i  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b SAARLAND UNIVERSITY   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e LURIC Study Nonprofit LLC   (Germany)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ SYNLAB ACADEMY   (Germany)

Author keywords

Cardiovascular death; Endogenous thrombin potential; Thrombin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; SERUM AMYLOID A; THROMBIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOGENOUS THROMBIN POTENTIAL; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; UNSTABLE ANGINA PECTORIS; BLOOD; CARDIOVASCULAR DISEASES; DEATH; EPIDEMIOLOGY; GERMANY; HEALTH STATUS; METABOLISM; MIDDLE AGED; MORTALITY; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DEATH; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; THROMBIN;

EID: 84906317654     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.026     Document Type: Article

References (47)

1. C.F. Semenkovich, and J.W. Heinecke The mystery of diabetes and atherosclerosis: time for a new plot Diabetes 46 1997 327 334 (Pubitemid 27090258)
2. N. Mackman Triggers, targets and treatments for thrombosis Nature 451 2008 914 918
3. P. Theroux, F. Perez-Villa, D. Waters, J. Lesperance, F. Shabani, and R. Bonan Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction Circulation 91 1995 2132 2139
4. V. Jacomella, N. Corti, and M. Husmann Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease Curr Opin Pharmacol 13 2013 294 300
5. S.B. Olsson Executive Steering Committee of the SIIII. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698 (Pubitemid 37468318)
6. J.N. Fiessinger, M.V. Huisman, and B.L. Davidson et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial JAMA 293 2005 681 689 (Pubitemid 40216038)
7. A. Iorio, F. Guercini, F. Ferrante, and G.G. Nenci Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism Curr Pharm Des 11 2005 3893 3918 (Pubitemid 41632245)
8. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
9. S. Schulman, A. Eelde, M. Blomback, and J. Stenflo The plasma concentration of activated protein C appears normal in patients with haemophilia Haemophilia 15 2009 566 570
10. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 2012 397 402
11. R. Artang, E. Rome, J.D. Nielsen, and H.J. Vidaillet Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors Am J Cardiol 112 2013 1973 1979
12. D. Ardissino, P.A. Merlini, and K.A. Bauer et al. Coagulation activation and long-term outcome in acute coronary syndromes Blood 102 2003 2731 2735 (Pubitemid 37248840)
13. I.M. Wichers, M.W. Tanck, and J.C. Meijers et al. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia Thromb Haemost 101 2009 465 470
14. S. Lekhal, T. Borvik, E. Brodin, A. Nordoy, and J.B. Hansen Tissue factor-induced thrombin generation in the fasting and postprandial state among elderly survivors of myocardial infarction Thromb Res 126 2010 353 359
15. P.Y. Hsue, R. Scherzer, and C. Grunfeld et al. HIV infection is associated with decreased thrombin generation Clin Infect Dis 54 2012 1196 1203
16. B.R. Winkelmann, W. Marz, and B.O. Boehm et al. Rationale and design of the LURIC study - a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease Pharmacogenomics 2 2001 S1 S73
17. H.D. Bruhn, and K.H. Zurborn The use of prothrombin fragment F1 + 2 to monitor the effect of oral anticoagulation J Heart Valve Dis 4 1995 138 140 (Pubitemid 26021270)
18. A. Gatt, J.J. van Veen, A.M. Woolley, S. Kitchen, P. Cooper, and M. Makris Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro Thromb Haemost 100 2008 350 355
19. P.L.A.S.C. Lp, A. Thompson, and P. Gao et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
20. P. Libby, and P.M. Ridker Inflammation and atherosclerosis: role of C-reactive protein in risk assessment Am J Med 116 Suppl. 6A 2004 9S 16S
21. K.D. O'Brien, and A. Chait Serum amyloid A: the "other" inflammatory protein Curr Atheroscler Rep 8 2006 62 68 (Pubitemid 43675756)
22. F. El-Atat, S.I. McFarlane, and J.R. Sowers Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management Curr Hypertens Rep 6 2004 215 223 (Pubitemid 39359564)
23. J. Kalz, H. ten Cate, and H.M. Spronk Thrombin generation and atherosclerosis J Thromb Thrombolysis 37 2014 45 55
24. J.S. Bae, and A.R. Rezaie Activated protein C inhibits high mobility group box 1 signaling in endothelial cells Blood 118 2011 3952 3959
25. J.H. Griffin Blood coagulation. The thrombin paradox Nature 378 1995 337 338
26. L.O. Mosnier, B.V. Zlokovic, and J.H. Griffin The cytoprotective protein C pathway Blood 109 2007 3161 3172 (Pubitemid 46572500)
27. L.O. Mosnier, and J.H. Griffin Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities Front Biosci 11 2006 2381 2399 (Pubitemid 43806554)
28. S.T. Loubele, C.A. Spek, and P. Leenders et al. Activated protein C protects against myocardial ischemia/reperfusion injury via inhibition of apoptosis and inflammation Arterioscler Thromb Vasc Biol 29 2009 1087 1092
29. S. Seehaus, K. Shahzad, and M. Kashif et al. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability Circulation 120 2009 774 784
30. J.S. Bae, and A.R. Rezaie Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms Thromb Res 125 2010 e9 e15
31. S.F. Mause, E. Ritzel, and E.A. Liehn et al. Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury Circulation 122 2010 495 506
32. I.J. Gudmundsdottir, I.L. Megson, and J.S. Kell et al. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans Circulation 114 2006 1625 1632 (Pubitemid 44547433)
33. G.C. Haralabopoulos, D.S. Grant, H.K. Kleinman, and M.E. Maragoudakis Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo Am J Physiol 273 1997 C239 C245
34. J.L. Strande, M.E. Widlansky, and N.E. Tsopanoglou et al. Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury Cardiovasc Res 83 2009 325 334
35. M. Smid, A.W. Dielis, and H.M. Spronk et al. Thrombin generation in the Glasgow myocardial infarction study PLoS One 8 2013 e66977
36. A. Undas, K. Szuldrzynski, K.E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K.G. Mann Systemic blood coagulation activation in acute coronary syndromes Blood 113 2009 2070 2078
37. M.G. Kok, J.C. Meijers, and S.J. Pinto-Sietsma Individuals with coronary artery disease at a young age and features of the metabolic syndrome have an increased prothrombotic potential Thromb Haemost 111 2014 458 464
38. M.J. Kenter, and A.F. Cohen Re-engineering the European Union clinical trials directive Lancet 379 2012 1765 1767
39. B.F. Gage Can we rely on RE-LY? N Engl J Med 361 2009 1200 1202
40. G.W. Albers, H.C. Diener, and L. Frison et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
41. L. Wallentin, R.G. Wilcox, and W.D. Weaver et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797 (Pubitemid 37093920)
42. A.F. Giglio, E. Basile, P. Santangeli, L. Di Biase, F. Trotta, and A. Natale Increased risk of myocardial infarction with dabigatran: fact or fiction? J Cardiovasc Med (Hagerstown) 15 2014 19 26
43. J.L. Mega, E. Braunwald, and S.D. Wiviott et al. Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
44. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
45. M.J. Krantz, and S. Kaul The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome ACS 2-thrombolysis in myocardial infarction 51) J Am Coll Cardiol 62 2013 777 781
46. K.W. Mahaffey, S.R. Stevens, and H.D. White et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial Eur Heart J 35 2014 233 241
47. J.W. Cheng, and G. Barillari Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions J Clin Pharm Ther 39 2014 118 135